How do you approach duration of immunotherapy in patients with metastatic NSCLC?
Does your approach depend on the patient’s response or PD-L1 level? Are there any studies supporting immunotherapy’s use beyond 2 years?
2 Answers
Mednet MemberInvited Expert
Medical Oncology · LSU Health Sciences Center New Orleans
Answered on
If someone manages to continue the ICI maintenance up to 2 years without progression, I am comfortable counseling the patient to stop the ICI treatment as per the regulatory approval indication. I have had occasionally, patient's anxiety level driving the desire to continue beyond the 2 years treatm...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Medical Oncology · University of Texas Health Science Center at Houston
Answered on
In patients with metastatic NSCLC on immunotherapy without progression at 2 years, I discuss with patients the option of stopping immunotherapy vs continuing it, and then we make a mutual decision in this regard. This is guided by this retrospective review from 2023.
Join for free or sign in to see the full answer